ESR1 and breast carcinoma: A total of 51 participants with ER+PR+HER2- or TNBC breast cancer were treated with neoadjuvant (n = 36) or adjuvant (n = 15) doxorubicin in combination with cyclophosphamide in the study by Todorova et al., 2020 [163].